EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

Figures & data

Table 1. Characteristics of the CML patients (n = 143)

Age (median (min-max))	44.6 (16–82)
Gender (Female/Male)	72/71
Splenomegaly (%)	63.6
Hb < 10 g/dl (%)	15.4
>1% basophils (%)	58.1
Thrombocytosis (>450 × 10^9/l) (%)	35.7
Thrombocytopenia (<150 × 10^9/l) (%)	8.4

n, number; Hb, hemoglobin; Plt, platelet

Table 2. The proportion of patients, predicted CCyR, and survival rates in each of the risk groups

Variables	Sokal	P value	Euro/Hasford	P value	EUTOS	P value
n (%)	115		115		117
Low risk	33 (28.6%)		52 (45.2%)		103 (88%)
Intermediate risk	41 (35.6%)		49 (42.6%)
High risk	41 (35.6%)		14 (12.2%)		14 (12%)
CCyR
Low risk	86.6%	0.08	78.0%	0.18	80.7%	<0.001
Intermediate risk	85.0%		77.5%
High risk	62.0%		53.8%		33.3%
EFS rate
Low risk	49.6%	0.3	53.6%	0.04	96.7%	<0.001
Intermediate risk	56.0%		50.2%
High risk	32.8%		10.4%		0.0%
OS rate
Low risk	100.0%	0.02	100.0%	0.01	96.7%	0.001
Intermediate risk	100.0%		97.4%
High risk	86.5%		73.9%		81.5%

n, number; CCyR, complete cytogenetic response; EFS, event-free survival; OS, overall survival.

Figure 1. Event-free survival for the low, intermediate, and high Sokal risk CML patients.

Figure 2. Event-free survival for the low, intermediate, and high Euro/Hasford risk CML patients.

Figure 3. Event-free survival for the low and high EUTOS risk CML patients.